Anti-EphA2 Antibody (1C1)
Based on 1 Customer Validation
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.9%
- Masse moléculaire:146.68 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
EphA2
Anti-EphA2 Antibody (1C1) shows human, mouse, rat, and cynomolgus monkey EphA2 binding affinities of 0.43, 0.92, 0.76 and 0.55 nM[1].
Anti-EphA2 Antibody (1C1) (10 μg/mL; 6 h) induces degradation of EphA2 protein in PC3 human prostate cancer cells and F98 rat glioma cells[1].
Anti-EphA2 Antibody (1C1) (72 h) has no effect on the viability of PC3 human prostate cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 human prostate cancer cells, F98 rat glioma cells
-
Concentration:10 μg/mL
-
Incubation Time:20 min, 6 h
-
Result:Reduced EphA2 protein levels 6 hours after treatment of PC3 and F98 cells.
Showed no reduction in EphA2 protein levels at 20 minutes after treatment.
Anti-EphA2 Antibody (1C1) (conjugated with mcMMAF) (2.5-10 mg/kg; i.v.; once weekly) significantly inhibits growth of EphA2-expressing F98 glioma tumors in Fischer 344 rats without observable adverse effects[1].
Anti-EphA2 Antibody (1C1) (conjugated with mcMMAF) (5 mg/kg; i.v.; once weekly) does not inhibit growth of non-EphA2-expressing RG2 glioma tumors in Fischer 344 rats[1].
Anti-EphA2 Antibody (1C1) (conjugated with mcMMAF) (1-5 mg/kg; i.v.; single dose) induces 60% EphA2 degradation in PC3 tumors by 1 hour at 1 mg/kg, while a 5 mg/kg single dose induces >90% EphA2 degradation maintained for 6 days in PC3 prostate tumor-bearing nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (female, 4 to 6 weeks of age, implanted s.c. with 5×106 PC3 cells)[1]
-
Dosage:0.1 mg/kg; 1 mg/kg; 3 mg/kg
-
Administration:i.v.; once weekly; 5 weeks
-
Result:Induced tumor stasis at 1 mg/kg.
Induced tumor regressions at 3 mg/kg.
Showed significant tumor growth inhibition relative to control groups at 1 mg/kg and 3 mg/kg.
Caused no overt toxicities, animal deaths, or body weight changes in any treatment group.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of HepG2 cells with EphA2 (HY-P990627, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa(HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized EphA2 Protein, Human can bind MEDI-547. The EC50 for this effect is 12.25 ng/mL.
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 146.68 kDa
-
Color Colorless to light yellow
-
Synonyms
MEDI-547 antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Jackson D, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008 Nov 15;68(22):9367-74. [Content Brief]
[2]. Peng L, et al. Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J Mol Biol. 2011;413(2):390-405. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-EphA2 Antibody (1C1) Related Classifications
HY-P990627 Related Classifications
Powered by Bioz